Frankfurt
22.05.26 | 08:03
0,088 Euro
+0,91 % +0,001
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain | 275 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma to Present at Redeye Investor Forum Online on May 21 | 213 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 13, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma to Present at ABG Investor Days on May 21 | 215 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 13, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 06.05. | AlzeCure Pharma: New scientific Article Published on TrkA-NAM ACD137 Against Osteoarthritic Pain | 306 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on... ► Artikel lesen | |
| 05.05. | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - March 2026 | 317 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its interim report for the period January - March 2026 is now available on the company's... ► Artikel lesen | |
| 30.04. | AlzeCure Pharma: Adjusted Timeline for the Previously Communicated Rights Issue | 484 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a biotech company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 29.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 29.04.2026 | 486 | Xetra Newsboard | Das Instrument FWR0 CA98873A1057 YUMY CANDY COMPANY INC. EQUITY wird cum Kapitalmassnahme gehandelt am 29.04.2026 und ex Kapitalmassnahme am 30.04.2026 The instrument FWR0 CA98873A1057 YUMY CANDY COMPANY... ► Artikel lesen | |
| 24.04. | AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million | 158 | ACCESS Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE RUSSIAN FEDERATION, BELARUS, AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND... ► Artikel lesen | |
| 20.04. | AlzeCure Pharma: Last Patient has Completed AlzeCure's Phase Ib Clinical Study with NeuroRestore ACD856 | 365 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 20, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 08.04. | AlzeCure Pharma Publishes its Annual Report for 2025 | 306 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 8, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 07.04. | AlzeCure Pharma to Present at Redeye Healthcare Day on April 14 | 311 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 7, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 01.04. | AlzeCure Pharma to Present at Redeye Alzheimer's Theme Event on April 9 | 279 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 19.03. | AlzeCure Pharma: AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer's Conference AD/PD | 479 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system,... ► Artikel lesen | |
| 04.03. | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11 | 337 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 4, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 26.02. | AlzeCure Pharma: AlzeCure Publishes its Year-End Report for January - December 2025 | 428 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available... ► Artikel lesen | |
| 24.02. | AlzeCure Pharma: Pain Project ACD440 Granted Orphan Drug Status in the EU | 927 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 24, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous... ► Artikel lesen | |
| 03.02. | AlzeCure Pharma: AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2026 | 822 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 3, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the... ► Artikel lesen | |
| 02.02. | AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam | 1.187 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 2, 2026 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 03.12.25 | AlzeCure Pharma: AlzeCure Receives Payment of EU Grant for Phase 2 Clinical Trial with NeuroRestore ACD856 for Alzheimer's Disease | 449 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / December 3, 2025 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system... ► Artikel lesen | |
| 11.11.25 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2025 | 350 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / November 11, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 368,90 | -1,13 % | Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults | ||
| VIATRIS | 14,106 | -0,44 % | Viatris's NDA For MR-107A-02 Secures FDA Acceptance | WASHINGTON (dpa-AFX) - Monday, Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for MR-107A-02 for the treatment of moderate-to-severe... ► Artikel lesen | |
| ALTIMMUNE | 2,565 | +1,99 % | H.C. Wainwright cuts Altimmune stock price target on dilution | ||
| SELLAS LIFE SCIENCES | 6,580 | +1,23 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update | - Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events - - First Patient Dosed in Phase 2 Trial of... ► Artikel lesen | |
| OPKO HEALTH | 1,070 | -2,73 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 3,445 | -0,72 % | Jaguar Health, Inc.: Jaguar Health Reports First Quarter 2026 Financials | Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi and Canalevia-CA1Company continues its focus on crofelemer... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 13,555 | +1,92 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,660 | -0,75 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 3,900 | -0,31 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces ... | - Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for... ► Artikel lesen | |
| PHOTOCURE | 6,080 | +1,33 % | Photocure: AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study | OSLO, Norway, May 18, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the presentation of two Photocure-supported abstracts at the American Urological... ► Artikel lesen | |
| LIPOCINE | 2,220 | 0,00 % | Lipocine Inc. - 8-K, Current Report | ||
| EUROBIO SCIENTIFIC | 21,400 | -4,46 % | Eurobio scientific signs definitive agreement to acquire CareDx's transplant Lab Product division | EUROBIO SCIENTIFIC SIGNS DEFINITIVE AGREEMENT TO ACQUIRE CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acquisition of CareDx's 'lab products' portfolio creates new opportunities for growth and innovation... ► Artikel lesen | |
| MEDICURE | 0,670 | +6,35 % | Medicure, Inc.: Medicure Announces AGM Results and Appointment of New Director | WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare... ► Artikel lesen | |
| BAYER | 38,910 | 0,00 % | Bayer liefert bessere Zahlen, doch die Aktie kommt nicht richtig los | Bei Bayer prallen derzeit zwei sehr unterschiedliche Geschichten aufeinander. Operativ konnte der Konzern zum Jahresauftakt durchaus überzeugen und vor allem im Agrargeschäft deutlich besser abschneiden... ► Artikel lesen | |
| MERCK KGAA | 126,40 | 0,00 % | Globaler Biotech-Wettlauf und die Zukunft der Plattformstrategie - Warum Mesoblast auf den Pfaden von großen Konzernen wie Merck KGaA wandert |
ALZECURE PHARMA AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,088 Euro und damit +0,91 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.